[In vitro susceptibilites to levofloxacin and various antibacterial agents of 11,475 clinical isolates obtained from 52 centers in 2002].
The susceptibilities of bacteria to fluoroquinolones (FQs), especially levofloxacin, and other antimicrobial agents were investigated using 11,475 clinical isolates collected in Japan during 2002. Methicillin susceptible staphylococci, Streptococcus pyogenes, Streptococcus pneumoniae, Moraxella catarrhalis, the family of Enterobactericeae, Haemophilus influenzae and Acinetobacter spp. exhibited stable and high susceptibilities to FQs. The rate of FQs-resistant MRSA was 80 approximately 90%, being markedly higher than that of FQs-resistant MSSA. The FQs-resistance rate of MRCNS was also higher than that of MSCNS, however, it was lower than that of MRSA. No FQs-resistant clinical isolates of Salmonella spp. were detected in any of the surveys. Thirteen of Escherichai coli 696 isolates, 8 of Klebsiella pneumoniae 630 isolates and 33 of Proteus mirabilis 373 isolates produced extended-spectrum beta-lactamase (ESBL), furthermore 6 of 13 in E. coli, 1 of 8 in K. pneumoniae and 14 of 31 ESBL-producing isolates, and in P. mirabilis were FQs resistant. Attention should be focused in the future on the emergence of ESBL in relation to FQs resistance. The rate of FQs-resistant P. aeruginosa isolated from urinary tract infection (UTI) was 40 approximately 60%, while 15 approximately 25% of isolates from respiratory tract infection (RTI) were resistant. IMP-1 type metallo beta-lactamase producing organisms were found in 49 of P. aeruginosa 1,095 isolates, 7 of S. marcescens 586 isolates and 4 of Acinetobacter spp. 474 isolates, respectively. Glycopeptide-resistant enterococci or S. aureus was not found.
Yamaguchi
Keizo
K
Department of Microbiology, Toho University School of Medicine.
Ohno
Akira
A
Kashitani
Fusako
F
Iwata
Morihiro
M
Kanda
Makoto
M
Tsujio
Yoshiko
Y
Shimoyama
Norihiko
N
Okujima
Hidetoshi
H
Ito
Minoru
M
Kawaguchi
Hideaki
H
Chiba
Hitoshi
H
Akizawa
Koji
K
Katayama
Yosei
Y
Sugimoto
Kumiko
K
Tashiro
Hiromi
H
Kaimori
Mitsuomi
M
Suwabe
Akira
A
Obata
Ritsuko
R
Sugiyama
Tatsuro
T
Toyoshima
Shunkoh
S
Kato
Jun
J
Kaku
Mitsuo
M
Kanemitsu
Keiji
K
Kunishima
Hiroyuki
H
Okada
Jun
J
Tazawa
Yoko
Y
Igari
Jun
J
Oguri
Toyoko
T
Watanabe
Kiyoaki
K
Kobayashi
Yoshio
Y
Uchida
Hiroshi
H
Totsuka
Kyoichi
K
Kon
Shinichiro
S
Nakamura
Katsuji
K
Matsuda
Keiko
K
Hayashi
Izumi
I
Shiotani
Joji
J
Shiotani
Joji
J
Kanno
Harushige
H
Itoh
Akira
A
Sumitomo
Midori
M
Uchida
Takashi
T
Kawabata
Atushi
A
Oiwa
Chikashi
C
Iwata
Masamitsu
M
Horii
Toshinobu
T
Ishigo
Shiomi
S
Yoshimura
Taira
T
Ichiyama
Satoshi
S
Wada
Yasunao
Y
Kimura
Satoshi
S
Maesaki
Shigefumi
S
Itoh
Kouichi
K
Noda
Yasunobu
Y
Yamashita
Takanori
T
Yamaguchi
Ikuo
I
Kageyama
Fumio
F
Shaku
Etsuko
E
Baba
Hisashi
H
Inuzuka
Kazuhisa
K
Okabe
Hidetoshi
H
Tatewaki
Kenichi
K
Moro
Kunihiko
K
Aihara
Masanori
M
Matsushima
Toshiharu
T
Niki
Yoshihito
Y
Kuw Abara
Masao
M
Ikawa
Siro
S
Tanaka
Mobuaki
M
Hinoda
Yasuharu
Y
Sugiura
Tetsuro
T
Kamioka
Mikio
M
Ono
Junko
J
Takata
Tohru
T
Makino
Hideichi
H
Murase
Mitsuharu
M
Miyamoto
Hisashi
H
Aizawa
Hisamichi
H
Honda
Junichi
J
Takii
Masahide
M
Nagasawa
Zenzo
Z
Aoki
Yosuke
Y
Hamazaki
Naotaka
N
Tsutsui
Toshiharu
T
Nakagawa
Keiichi
K
Iwata
Morihiro
M
Hiramatsu
Kazufumi
K
Saikawa
Tetsunori
T
Yamane
Nobuhisa
N
Kimoto
Hiroya
H
Kotani
Tomio
T
Kageoka
Takeshi
T
Hongo
Toshiharu
T
Masuda
Junichi
J
Miyanohara
Hiroaki
H
Tsujimura
Masayuki
M
Yasujima
Minoru
M
Hayashi
Izumi
I
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial; D004926:Escherichia coli / Q000187:drug effects; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D006801:Humans; D064704:Levofloxacin; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D015242:Ofloxacin / Q000494:pharmacology*; D013211:Staphylococcus aureus / Q000187:drug effects
D000900:Anti-Bacterial Agents; D064704:Levofloxacin; D015242:Ofloxacin